Viridian Therapeutics, Inc. (VRDN)

NCM – Real vaqt narxi. Valyuta: USD

22.94

-0.03 (-0.13%)

Bozor ochiq: Aug 12, 2026, 3:22 PM EDT

22.98

+0.01 (0.04%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Viridian Therapeutics, Inc. (VRDN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Search stocks

Viridian Therapeutics, Inc. (VRDN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results